Pharmacokinetic–Pharmacodynamic Vedolizumab Model Targets Endoscopic Remission in CD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
Inflamm. Bowel Dis. 2021 Jun 17;[EPub Ahead of Print], J Hanzel, E Dreesen, S Vermeire, M Löwenberg, F Hoentjen, P Bossuyt, E Clasquin, FJ Baert, GR D'Haens, R MathôtFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.